Validation of Brain Angiotensin System Blockade as a Novel Drug Target in Pharmacological Treatment of Neuropsychiatric Disorders

 

 Buy Article Permissions and Reprints

Abstract

Retreat in psychiatric drug development results in innovative medication decline that might be at least partially overcome by adjunct therapy. New evidence from clinical studies has shown a possible role for brain Renin-Angiotensin System (RAS) in both affective and psychotic disorders. Simultaneously, rapidly accumulating data from basic studies indicate effectiveness of central RAS blockade in much broader range of neuropsychiatric disease. Recent findings implicate brain RAS, especially Angiotensin II (Ang II), in neural pathophysiology of mental disorders through neuroendocrine modulation and effects on neurotransmitter release, mostly noradrenaline, acetylcholine and dopamine. The potential effects of angiotensin-converting-enzyme (ACE) inhibition and angiotensin type 1 receptor (AT1R) blockade on treatment of mental disorders are a matter of considerable interest. This review describes involvement of brain RAS in pathophysiology of neuropsychiatric disorders and an intriguing possibilities of improvement in pharmacological treatment outcome, where using angiotensin-converting-enzyme inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB), goes beyond blood pressure control.

• References

• 1 O'Donnell P, Ehlers MD. Opportunities for new drug development in psychiatry: a glass half-full. JAMA Psychiatry 2015; 72: 1067-1068
  CrossrefPubMedGoogle Scholar
• 2 Scannell JW, Bosley J. When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis. PLoS One 2016; 11: e0147215
  CrossrefPubMedGoogle Scholar
• 3 Global Burden of Disease (GBD). World Health Organization 2012;
  PubMed
• 4 Bloom DE, Cafiero ET, Jané-Llopis E. et al. The global economic burden of non-communicable diseases. Geneva: World Economic Forum; 2011
  Google Scholar
• 5 Wright JW, Harding JW. The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases. Pflugers. Arch 2013; 465: 133-151
  CrossrefPubMedGoogle Scholar
• 6 Nasr SJ, Crayton JW, Agarwal B. et al. Lower frequency of antidepressant use in patients on renin-angiotensin-aldosterone system modifying medications. Cell Mol Neurobiol 2011; 31: 615-618
  CrossrefPubMedGoogle Scholar
• 7 Murck H, Schüssler P, Steiger A. Renin-angiotensin-aldosterone system: the forgotten stress hormone system: relationship to depression and sleep. Pharmacopsychiatry 2012; 45: 83-95
  Article in Thieme ConnectPubMedGoogle Scholar
• 8 Hayes LH, Sawa A. Angiotensin signaling in the development and pathology of immune-associated psychosis. Schizophr Bull 2015; 41 (Suppl. 01) S4
  CrossrefPubMedGoogle Scholar
• 9 Saavedra JM. Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin Sci (Lond) 2012; 123: 567-590
  CrossrefPubMedGoogle Scholar
• 10 Anderson C. More indirect evidence of potential neuroprotective benefits of Angiotensin receptor blockers. J Hypertens 2010; 28: 429
  CrossrefPubMedGoogle Scholar
• 11 Li NC, Lee A, Whitmer RA. et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465
  CrossrefPubMedGoogle Scholar
• 12 Pavlatou MG, Mastorakos G, Lekakis I. et al. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. Stress 2008; 11: 62-72
  CrossrefPubMedGoogle Scholar
• 13 Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004; 21: 377-393
  CrossrefPubMedGoogle Scholar
• 14 Braszko JJ, Wincewicz D, Jakubów P. Candesartan prevents impairment of recall caused by repeated stress in rats. Psychopharmacology (Berl) 2013; 225: 421-428
  CrossrefPubMedGoogle Scholar
• 15 Wincewicz D, Braszko JJ. Telmisartan attenuates cognitive impairment caused by chronic stress in rats. Pharmacol Rep 2014; 66: 436-441
  CrossrefPubMedGoogle Scholar
• 16 Wincewicz D, Braszko JJ. Angiotensin II AT1 receptor blockade by telmisartan reduces impairment of spatial maze performance induced by both acute and chronic stress. J Renin Angiotensin Aldosterone Syst 2015; 16: 495-505
  CrossrefPubMedGoogle Scholar
• 17 Wincewicz D, Juchniewicz A, Waszkiewicz N. et al. Angiotensin II type 1 receptor blockade by telmisartan prevents stress-induced impairment of memory via HPA axis deactivation and up-regulation of brain-derived neurotrophic factor gene expression. Pharmacol Biochem Behav 2016; 148: 108-118
  CrossrefPubMedGoogle Scholar
• 18 Erhardt A, Ising M, Unschuld PG. et al. Regulation of the hypothalamic–pituitary–adrenocortical system in patients with panic disorder. Neuropsychopharmacology 2006; 31: 2515-2522
  CrossrefPubMedGoogle Scholar
• 19 Corcoran C, Mujica-Parodi L, Yale S. et al. Could stress cause psychosis in individuals vulnerable to schizophrenia?. CNS Spectr 2002; 7: 33-38 41-42
  CrossrefPubMedGoogle Scholar
• 20 Lo Sauro C, Ravaldi C, Cabras PL. et al. Stress, hypothalamic-pituitary-adrenal axis and eating disorders. Neuropsychobiology 2008; 57: 95-115
  CrossrefPubMedGoogle Scholar
• 21 Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 2000; 48: 755-765
  CrossrefPubMedGoogle Scholar
• 22 Popoli M, Yan Z, McEwen BS. et al. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 2011; 13: 22-37
  CrossrefPubMedGoogle Scholar
• 23 Chetty S, Friedman AR, Taravosh-Lahn K. et al. Stress and glucocorticoids promote oligodendrogenesis in the adult hippocampus. Mol Psychiatry 2014; 19: 1275-1283
  CrossrefPubMedGoogle Scholar
• 24 Keller PA, McCluskey A, Morgan J. et al. The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments. Arch Pharm (Weinheim) 2006; 339: 346-355
  CrossrefPubMedGoogle Scholar
• 25 Yang G, Wan Y, Zhu Y. Angiotensin II--an important stress hormone. Biol Signals 1996; 5: 1-8
  CrossrefPubMedGoogle Scholar
• 26 Bregonzio C, Seltzer A, Armando I. et al. Angiotensin II AT(1)receptor blockade selectively enhances brain AT(2) receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive rats. Stress 2008; 6: 457-466
  PubMedGoogle Scholar
• 27 Israel A, Stromberg C, Tsutsumi K. et al. Angiotensin II receptor subtypes and phosphoinositide hydrolysis in rat adrenal medulla. Brain Res Bull 1995; 38: 441-446
  CrossrefPubMedGoogle Scholar
• 28 Von Bohlen und Halbach O, Albrecht D. Mapping of angiotensin AT1 receptors in the rat limbic system. Regul Pept 1998; 78: 51-56
  CrossrefPubMedGoogle Scholar
• 29 Lenkei Z, Palkovits M, Corvol P. et al. Distribution of angiotensin type-1 receptor messenger RNA expression in the adult rat brain. Neuroscience 1998; 82: 827-841
  PubMedGoogle Scholar
• 30 Schulkin J. Angst and the amygdala. Dialogues Clin Neurosci 2006; 8: 407-416
  PubMedGoogle Scholar
• 31 Aguilera G, Kiss A, Luo X. Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. J Neuroendocrinol 1995; 7: 775-783
  CrossrefPubMedGoogle Scholar
• 32 Oldfield BJ, Davern PJ, Giles ME. et al. Efferent neural projections of angiotensin receptor (AT1) expressing neurons in the hypothalamic paraventricular nucleus of the rat. J Neuroendocrinol 2001; 13: 139-146
  CrossrefPubMedGoogle Scholar
• 33 Wright JW, Harding JW. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev 1994; 18: 21-53
  CrossrefPubMedGoogle Scholar
• 34 Cierco M, Israel A. Role of angiotensin AT1 receptor in the cardiovascular response to footshock. Eur J Pharmacol 1994; 251: 103-106
  CrossrefPubMedGoogle Scholar
• 35 Kregel KC, Stauss H, Unger T. Modulation of autonomic nervous system adjustments to heat stress by central ANG II receptor antagonism. Am J Physiol 1994; 266: R1985-R1991
  PubMedGoogle Scholar
• 36 Saiki Y, Watanabe T, Tan N. et al. Role of central ANGII receptors in stress-induced cardiovascular and hyperthermic responses in rats. Am J Physiol 1997; 272: R26-R33
  PubMedGoogle Scholar
• 37 Armando I, Carranza A, Nishimura Y. et al. Peripheral administration of an angiotensin I AT1 receptor antagonist decreases the hypothalamic-pituitary-adrenal response to stress. Endocrinology 2001; 142: 3880-3889
  CrossrefPubMedGoogle Scholar
• 38 Saavedra JM, Ando H, Armando I. et al. Anti-stress and anti-anxiety effects of centrally acting angiotensin II AT1 receptor antagonists. Regul Pept 2005; 128: 227-238
  CrossrefPubMedGoogle Scholar
• 39 Zhenfeng Z, Huilan S, Junya J. et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; 12: 365-374
  CrossrefPubMedGoogle Scholar
• 40 Raasch W, Wittmershaus C, Dendorfer A. et al. Angiotensin II inhibition reduces stress sensitivity of hypothalamo-pituitary-adrenal axis in spontaneously hypertensive rats. Endocrinology 2006; 147: 3539-3546
  CrossrefPubMedGoogle Scholar
• 41 Steckelings UM, Kaschina E, Unger T. The AT2 receptor--a matter of love and hate. Peptides 2005; 26: 1401-1409
  CrossrefPubMedGoogle Scholar
• 42 Steckelings UM, Rompe F, Kaschina E. et al. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst 2010; 11: 67-73
  CrossrefPubMedGoogle Scholar
• 43 Li J, Culman J, Hörtnagl H. et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 2005; 19: 617-619
  CrossrefPubMedGoogle Scholar
• 44 Steckelings UM, Unger T. Angiotensin II type 2 receptor agonists--where should they be applied?. Expert Opin Investig Drugs 2012; 21: 763-766
  CrossrefPubMedGoogle Scholar
• 45 Schinke M, Baltatu O, Böhm M. et al. Blood pressure reduction and diabetes insipidus in transgenic rats deficient in brain angiotensinogen. Proc Natl Acad Sci USA 1999; 96: 3975-3980
  CrossrefPubMedGoogle Scholar
• 46 Foulquier S, Steckelings UM, Unger T. Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep 2012; 14: 403-409
  CrossrefPubMedGoogle Scholar
• 47 Seltzer A, Bregonzio C, Armando I. et al. Oral administration of an AT1 receptor antagonist prevents the central effects of angiotensin II in spontaneously hypertensive rats. Brain Res 2004; 1028: 9-18
  CrossrefPubMedGoogle Scholar
• 48 McCarthy CA, Vinh A, Miller AA. et al. Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One 2014; 9: e95762
  CrossrefPubMedGoogle Scholar
• 49 Fouda AY, Pillai B, Dhandapani KM. et al. Role of interleukin-10 in the neuroprotective effect of the angiotensin type 2 receptor agonist, compound 21, after ischemia/reperfusion injury. Eur J Pharmacol 2017; 799: 128-134
  CrossrefPubMedGoogle Scholar
• 50 Wright JW, Harding JW. The angiotensin AT4 receptor subtype as a target for the treatment of memory dysfunction associated with Alzheimer's disease. J Renin Angiotensin Aldosterone Syst 2008; 9: 226-237
  CrossrefPubMedGoogle Scholar
• 51 Yasuda N, Miura S, Akazawa H. et al. Conformational switch of angiotensin II type 1 receptor underlying mechanical stress-induced activation. EMBO Rep 2008; 9: 179-186
  CrossrefPubMedGoogle Scholar
• 52 Bondi CO, Rodriguez G, Gould GG. et al. Chronic unpredictable stress induces a cognitive deficit and anxiety-like behavior in rats that is prevented by chronic antidepressant drug treatment. Neuropsychopharmacology 2008; 33: 320-331
  CrossrefPubMedGoogle Scholar
• 53 Oveisgharan S, Hachinski V. Hypertension, executive dysfunction, and progression to dementia: the Canadian study of health and aging. Arch Neurol 2010; 67: 187-192
  PubMedGoogle Scholar
• 54 Ciobica A, Bild W, Hritcu L. et al. Brain renin-angiotensin system in cognitive function: pre-clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 2009; 109: 171-180
  PubMedGoogle Scholar
• 55 Kang HG, Mahoney DF, Hoenig H. et al. Center for Integration of Medicine and Innovative Technology Working Group on Advanced Approaches to Physiologic Monitoring for the Aged. In situ monitoring of health in older adults: technologies and issues. J Am Geriatr Soc 2010; 58: 1579-1586
  CrossrefPubMedGoogle Scholar
• 56 Hajjar I, Hart M, Chen YL. et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med 2012; 172: 442-444
  CrossrefPubMedGoogle Scholar
• 57 Li NC, Lee A, Whitmer RA. et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465
  CrossrefPubMedGoogle Scholar
• 58 Kume K, Hanyu H, Sakurai H. et al. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int 2012; 12: 207-214
  CrossrefPubMedGoogle Scholar
• 59 Black SE. Telmisartan vs. perindopril in hypertensive mild-moderate Alzheimer’s disease patients (SARTAN-AD). Alzheimer’s Drug Discovery Foundation. www.clinicalTrials.gov Identifier: NCT02085265
  PubMed
• 60 Horiuchi M, Mogi M, Iwai M. The angiotensin II type 2 receptor in the brain. J Renin Angiotensin Aldosterone Syst 2010; 11: 1-6
  CrossrefPubMedGoogle Scholar
• 61 Ongali B, Nicolakakis N, Tong XK. et al. Angiotensin II type 1 receptor blocker losartan prevents and rescues cerebrovascular, neuropathological and cognitive deficits in an Alzheimer’s disease model. Neurobiol Dis 2014; 68: 126-136
  CrossrefPubMedGoogle Scholar
• 62 Kurata T, Lukic V, Kozuki M. et al. Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO. Transl Stroke Res 2015; 6: 107-115
  CrossrefPubMedGoogle Scholar
• 63 Torika N, Asraf K, Danon A. et al. Telmisartan modulates glial activation: in vitro and in vivo studies. PLoS One 2016; 11: e0155823
  CrossrefPubMedGoogle Scholar
• 64 Pelisch N, Hosomi N, Ueno M. et al. Blockade of AT1 receptors protects the blood–brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens 2011; 24: 362-368
  CrossrefPubMedGoogle Scholar
• 65 Braszko JJ, Kupryszewski G, Witczuk B. et al. Angiotensin II (3-8)-hexapeptide affects motor activity, performance of passive avoidance, and a conditioned avoidance response in rats. Neuroscience 1988; 27: 777-783
  CrossrefPubMedGoogle Scholar
• 66 Albiston AL, Allen AM, Mendelsohn FA. et al. Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004; 124: 341-349
  CrossrefPubMedGoogle Scholar
• 67 Braszko JJ, Walesiuk A, Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J Renin Angiotensin Aldosterone Syst 2006; 7: 168-174
  CrossrefPubMedGoogle Scholar
• 68 Vanderheyden PM. From angiotensin IV binding site to AT4 receptor. Mol Cell Endocrinol 2009; 302: 159-166
  CrossrefPubMedGoogle Scholar
• 69 Lee J, Chai SY, Mendelsohn FA. et al. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacol 2001; 40: 618-623
  CrossrefPubMedGoogle Scholar
• 70 Braszko JJ. Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV. Peptides 2004; 25: 1195-1203
  CrossrefPubMedGoogle Scholar
• 71 Hamanoue M, Takemoto N, Matsumoto K. et al. Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. J Neurosci Res 1996; 43: 554-564
  CrossrefPubMedGoogle Scholar
• 72 Kawas LH, McCoy AT, Yamamoto BJ. et al. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers. J Pharmacol Exp Ther 2012; 340: 539-548
  CrossrefPubMedGoogle Scholar
• 73 Zubenko GS, Nixon RA. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry 1984; 141: 110-111
  CrossrefPubMedGoogle Scholar
• 74 Deicken RF. Captopril treatment of depression. Biol Psychiatry 1986; 21: 1425-1428
  CrossrefPubMedGoogle Scholar
• 75 Germain L, Chouinard G. Treatment of recurrent unipolar major depression with captopril. Biol Psychiatry 1988; 23: 637-641
  CrossrefPubMedGoogle Scholar
• 76 Germain L, Chouinard G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry 1989; 25: 489-493
  CrossrefPubMedGoogle Scholar
• 77 Braszko JJ, Karwowska-Polecka W, Halicka D. et al. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol 2003; 14: 323-343
  PubMedGoogle Scholar
• 78 Nasr SJ, Crayton JW, Agarwal B. et al. Lower frequency of antidepressant use in patients on renin-angiotensin-aldosterone system modifying medications. Cell Mol Neurobiol 2011; 31: 615-618
  CrossrefPubMedGoogle Scholar
• 79 Ancelin ML, Carrière I, Scali J. et al. Angiotensin-converting enzyme gene variants are associated with both cortisol secretion and late-life depression. Transl Psychiatry 2013; 3: e322
  CrossrefPubMedGoogle Scholar
• 80 Saab YB, Gard PR, Yeoman MS. et al. Renin-angiotensin-system gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1113-1118
  CrossrefPubMedGoogle Scholar
• 81 Kucukali CI, Aydin M, Ozkok E. et al. Angiotensin-converting enzyme polymorphism in schizophrenia, bipolar disorders, and their first-degree relatives. Psychiatr Genet 2010; 20: 14-19
  CrossrefPubMedGoogle Scholar
• 82 Fudalej S, Fudalej M, Kostrzewa G. et al. Angiotensin-converting enzyme polymorphism and completed suicide: an association in Caucasians and evidence for a link with a method of self-injury. Neuropsychobiology 2009; 59: 151-158
  CrossrefPubMedGoogle Scholar
• 83 Baghai TC, Binder EB, Schule C. et al. Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity, and hypercortisolism. Mol Psychiatry 2006; 11: 1003-1015
  CrossrefPubMedGoogle Scholar
• 84 Kondo DG, Speer MC, Krishnan KR. et al. Association of AGTR1 with 18-month treatment outcome in late-life depression. Am J Geriatr Psychiatry 2007; 15: 564-572
  CrossrefPubMedGoogle Scholar
• 85 Scherrer JF, Hong X, Bucholz KK. et al. A twin study of depression symptoms, hypertension, and heart disease in middle-aged men. Psychosom Med 2003; 65: 548-557
  CrossrefPubMedGoogle Scholar
• 86 Okuyama S, Sakagawa T, Sugiyama F. et al. Reduction of depressive-like behavior in mice lacking angiotensinogen. Neurosci Lett 1999; 261: 167-170
  CrossrefPubMedGoogle Scholar
• 87 Gard PR, Mandy A, Sutcliffe MA. Evidence of a possible role of altered angiotensin function in the treatment, but not etiology, of depression. Biol Psychiatry 1999; 45: 1030-1034
  CrossrefPubMedGoogle Scholar
• 88 Ferguson AV, Washburn DL, Latchford KJ. Hormonal and neurotransmitter roles for angiotensin in the regulation of central autonomic function. Exp Biol Med (Maywood) 2001; 226: 85-96
  CrossrefPubMedGoogle Scholar
• 89 McKinley MJ, Albiston AL, Allen AM. et al. The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol 2003; 35: 901-918
  CrossrefPubMedGoogle Scholar
• 90 Fabiani ME, Sourial M, Thomas WG. et al. enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: implications for the pathophysiology of benign prostatic hyperplasia. J Endocrinol 2001; 171: 97-108
  CrossrefPubMedGoogle Scholar
• 91 Vatta MS, Bianciotti LG, Locatelli AS. et al. Monophasic and biphasic effects of angiotensin II and III on norepinephrine uptake and release in rat adrenal medulla. Can J Physiol Pharmacol 1992; 70: 821-825
  CrossrefPubMedGoogle Scholar
• 92 Grupp LA, Perlanski E, Stewart RB. Attenuation of alcohol intake by a serotonin uptake inhibitor: evidence for mediation through the renin-angiotensin system. Pharmacol Biochem Behav 1988; 30: 823-837
  CrossrefPubMedGoogle Scholar
• 93 Tanaka J, Kariya K, Nomura M. Angiotensin II reduces serotonin release in the rat subfornical organ area. Peptides 2003; 24: 881-887
  CrossrefPubMedGoogle Scholar
• 94 Jenkins TA. Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats. Neurosci Lett 2008; 444: 186-189
  CrossrefPubMedGoogle Scholar
• 95 Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity. Dev Neurobiol 2010; 70: 289-297
  CrossrefPubMedGoogle Scholar
• 96 Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016; 16: 22-34
  CrossrefPubMedGoogle Scholar
• 97 Sánchez-Lemus E, Benicky J, Pavel J. et al. In vivo angiotensin II AT1 receptor blockade selectively inhibits LPS-induced innate immune response and ACTH release in rat pituitary gland. Brain Behav Immun 2009; 23: 945-957
  CrossrefPubMedGoogle Scholar
• 98 Kono S, Kurata T, Sato K. et al. Neurovascular protection by telmisartan via reducing neuroinflammation in stroke-resistant spontaneously hypertensive rat brain after ischemic stroke. J Stroke Cerebrovasc Dis 2015; 24: 537-547
  CrossrefPubMedGoogle Scholar
• 99 Xu Y, Xu Y, Wang Y. et al. Telmisartan prevention of LPS-induced microglia activation involves M2 microglia polarization via CaMKKβ-dependent AMPK activation. Brain Behav Immun 2015; 50: 298-313
  CrossrefPubMedGoogle Scholar
• 100 Bhat SA, Goel R, Shukla R. et al. Angiotensin receptor blockade modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation better than angiotensin-converting enzyme inhibition. Mol Neurobiol 2016; 53: 6950-6967
  CrossrefPubMedGoogle Scholar
• 101 Liu F, Havens J, Yu Q. et al. The link between angiotensin II-mediated anxiety and mood disorders with NADPH oxidase-induced oxidative stress. Int J Physiol Pathophysiol Pharmacol 2012; 4: 28-35
  PubMedGoogle Scholar
• 102 Duric V, Banasr M, Licznerski P. et al. A negative regulator of MAP kinase causes depressive behavior. Nat Med 2010; 16: 1328-1332
  CrossrefPubMedGoogle Scholar
• 103 Lam RW, Levitan RD. Pathophysiology of seasonal affective disorder: a review. J Psychiatry Neurosci 2000; 25: 469-480
  PubMedGoogle Scholar
• 104 Baltatu O, Lippoldt A, Hansson A. et al. Local renin-angiotensin system in the pineal gland. Brain Res Mol Brain Res 1998; 54: 237-242
  CrossrefPubMedGoogle Scholar
• 105 Campos LA, Cipolla-Neto J, Amaral FG. et al. The angiotensin-melatonin axis. Int J Hypertens 2013; 2013: 521783
  PubMedGoogle Scholar
• 106 Baltatu O, Afeche SC, José dos Santos SH. et al. Locally synthesized angiotensin modulates pineal melatonin generation. J Neurochem 2002; 80: 328-334
  CrossrefPubMedGoogle Scholar
• 107 Ishigaki S, Ohashi N, Isobe S. et al. Impaired endogenous nighttime melatonin secretion relates to intrarenal renin-angiotensin system activation and renal damage in patients with chronic kidney disease. Clin Exp Nephrol 2016; 20: 878-884
  CrossrefPubMedGoogle Scholar
• 108 Corcoran C, Mujica-Parodi L, Yale S. et al. Could stress cause psychosis in individuals vulnerable to schizophrenia?. CNS Spectr 2002; 7: 33-38 41–2
  CrossrefPubMedGoogle Scholar
• 109 Gejman PV, Sanders AR, Duan J. The role of genetics in the etiology of schizophrenia. Psychiatr Clin North Am 2010; 33: 35-66
  CrossrefPubMedGoogle Scholar
• 110 Gadelha A, Yonamine CM, Ota VK. et al. ACE I/D genotype-related Increase in ACE plasma enzymatic activity is a better predictor of Schizophrenia diagnosis than ACE I/D genotypes alone. Schizophr Res 2015; 164: 109-114
  CrossrefPubMedGoogle Scholar
• 111 Song GG, Lee YH. The insertion/deletion polymorphism in the angiotensin-converting enzyme and susceptibility to schizophrenia or Parkinson's disease: A meta-analysis. J Renin Angiotensin Aldosterone Syst 2015; 16: 434-442
  CrossrefPubMedGoogle Scholar
• 112 Kucukali CI, Aydin M, Ozkok E. et al. Angiotensin-converting enzyme polymorphism in schizophrenia, bipolar disorders, and their first-degree relatives. Psychiatr Genet 2010; 20: 14-19
  CrossrefPubMedGoogle Scholar
• 113 Thakur KS, Prakash A, Bisht R. et al. Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. J Renin Angiotensin Aldosterone Syst 2015; 16: 917-929
  CrossrefPubMedGoogle Scholar
• 114 Martin S, Markus MA, Morris BJ. et al. Does angiotensin interact with dopaminergic mechanisms in the brain to modulate prepulse inhibition in mice?. Neuropharmacology 2008; 54: 399-404
  CrossrefPubMedGoogle Scholar
• 115 Brown DC, Steward LJ, Ge J. et al. Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo. Br J Pharmacol 1996; 118: 414-420
  CrossrefPubMedGoogle Scholar
• 116 Gendron L, Payet MD, Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J Mol Endocrinol 2003; 31: 359-372
  CrossrefPubMedGoogle Scholar
• 117 Binder EB, Kinkead B, Owens MJ. et al. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 2001; 50: 856-872
  CrossrefPubMedGoogle Scholar
• 118 Tooney PA, Crawter VC, Chahl LA. Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol Psychiatry 2001; 49: 523-527
  CrossrefPubMedGoogle Scholar
• 119 Arregui A, Mackay AV, Spokes EG. et al. Reduced activity of angiotensin-converting enzyme in basal ganglia in early onset schizophrenia. Psychol Med 1980; 10: 307-313
  CrossrefPubMedGoogle Scholar
• 120 Beckmann H, Saavedra JM, Gattaz WF. Low angiotensin-converting enzyme activity (kininase II) in cerebrospinal fluid of schizophrenics. Biol Psychiatry 1984; 19: 679-684
  PubMedGoogle Scholar
• 121 Wahlbeck K, Rimon R, Fyhrquist F. Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic-treated schizophrenic patients. Schizophr Res 1993; 9: 77-82
  CrossrefPubMedGoogle Scholar
• 122 Wahlbeck K, Ahokas A, Miettinen K. et al. Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free patients with schizophrenia. Schizophr Bull 1998; 24: 391-397
  CrossrefPubMedGoogle Scholar
• 123 Baskan NM, Basaran A, Yenilmez C. et al. Investigation of association between angiotensin-converting enzyme gene insertion/deletion polymorphism frequency in Turkish patients with schizophrenia. Genet Test Mol Biomarkers 2010; 14: 753-757
  CrossrefPubMedGoogle Scholar
• 124 Gadelha A, Vendramini AM, Yonamine CM. et al. Convergent evidences from human and animal studies implicate angiotensin I-converting enzyme activity in cognitive performance in schizophrenia. Transl Psychiatry 2015; 5: e691
  CrossrefPubMedGoogle Scholar
• 125 Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 2006; 11 (Suppl. 07) 32-39
  CrossrefPubMedGoogle Scholar
• 126 Clasen R, Schupp M, Foryst-Ludwig A. et al. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137-143
  CrossrefPubMedGoogle Scholar
• 127 Benson SC, Pershadsingh HA, Ho CI. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002
  CrossrefPubMedGoogle Scholar
• 128 Yamagishi S, Nakamura K, Matsui T. Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr Mol Med 2007; 7: 463-469
  CrossrefPubMedGoogle Scholar
• 129 Michel MC, Foster C, Brunner HR. et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013; 65: 809-848
  CrossrefPubMedGoogle Scholar
• 130 Takagi H, Niwa M, Mizuno Y. et al. Telmisartan as a metabolic sartan: the first metaanalysis of randomized controlled trials in metabolic syndrome. J Am Soc Hypertens 2013; 7: 229-235
  CrossrefPubMedGoogle Scholar
• 131 Huang GZ, Tang YH, Wang BY. et al. Effects of telmisartan on insulin resistance and visceral fat distribution in Chinese hypertensive patients with obesity. Saudi Med J 2011; 32: 1017-1021
  PubMedGoogle Scholar
• 132 Yamaguchi K, Tsutsumi E. The insulin sparing effect of telmisartan in a case of type 2 diabetes mellitus associated with schizophrenia under treatment of risperidone. Intern Med 2010; 49: 919-923
  CrossrefPubMedGoogle Scholar
• 133 Yamashita H, Yoda H, Kuroki N. et al. Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine. Psychopharmacology (Berl) 2011; 213: 1-9
  CrossrefPubMedGoogle Scholar
• 134 Ginty AT, Carroll D, Roseboom TJ. et al. Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle-aged men and women. J Hum Hypertens 27: 187-190
  PubMedGoogle Scholar
• 135 Suzman MM. Propranolol in the treatment of anxiety. Postgrad Med J 1976; 52 (Suppl. 04) 168-174
  PubMedGoogle Scholar
• 136 Steenen SA, van Wijk AJ, van der Heijden GJ. et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol 2016; 30: 128-139
  CrossrefPubMedGoogle Scholar
• 137 Armando I, Carranza A, Nishimura Y. et al. Peripheral administration of an angiotensin II AT1 receptor antagonist decreases the hypothalamic–pituitary–adrenal response to stress. Endocrinology 2001; 142: 3880-3889
  CrossrefPubMedGoogle Scholar
• 138 Krsková L, Vrabcová M, Talarovicová A. et al. Influence of up-regulated renin-angiotensin system on the exploration, anxiety-related behavior and object recognition. Acta Biol Hung 2009; 60: 369-383
  CrossrefPubMedGoogle Scholar
• 139 López LH, Caif F, García S. et al. Anxiolytic-like effect of losartan injected into amygdala of the acutely stressed rats. Pharmacol Rep 2012; 64: 54-63
  CrossrefPubMedGoogle Scholar
• 140 Marinzalda Mde L, Pérez PA, Gargiulo PA. et al. Fear-potentiated behaviour is modulated by central amygdala angiotensin II AT1 receptors stimulation. Biomed Res Int 2014; 2014: 183248
  PubMedGoogle Scholar
• 141 Srinivasan J, Suresh B, Ramanathan M. Differential anxiolytic effect of enalapril and losartan in normotensive and renal hypertensive rats. Physiol Behav 2003; 78: 585-591
  CrossrefPubMedGoogle Scholar
• 142 Hein L, Barsh GS, Pratt RE. et al. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. Nature 1995; 377: 744-747
  CrossrefPubMedGoogle Scholar
• 143 Ichiki T, Labosky PA, Shiota C. et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377: 748-750
  CrossrefPubMedGoogle Scholar
• 144 Braszko JJ, Kułakowska A, Winnicka MM. Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats. J Physiol Pharmacol 2003; 2: 271-281
  PubMedGoogle Scholar
• 145 Voigt JP, Hörtnagl H, Rex A. et al. Brain angiotensin and anxiety-related behavior: the transgenic rat TGR(ASrAOGEN)680. Brain Res 2005; 1046: 145-156
  CrossrefPubMedGoogle Scholar
• 146 Belcheva I, Georgiev V, Chobanova M. et al. Behavioral effects of angiotensin II microinjected into CA1 hippocampal area. Neuropeptides 1997; 31: 60-64
  CrossrefPubMedGoogle Scholar
• 147 Okuyama S, Sakagawa T, Chaki S. et al. Anxiety like behavior in mice lacking the angiotensin II type-2 receptor. Brain Res 1999; 821: 150-159
  CrossrefPubMedGoogle Scholar
• 148 Beyer CE, Dwyer JM, Platt BJ. et al. Angiotensin IV elevates oxytocin levels in the rat amygdala and produces anxiolytic-like activity through subsequent oxytocin receptor activation. Psychopharmacology (Berl) 2010; 209: 303-311
  CrossrefPubMedGoogle Scholar
• 149 Pavel J, Benicky J, Murakami Y. et al. Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann N Y Acad Sci 2008; 1148: 360-366
  CrossrefPubMedGoogle Scholar
• 150 Nutt DJ, Malizia AL. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 2001; 179: 390-396
  CrossrefPubMedGoogle Scholar
• 151 Saavedra JM, Armando I, Bregonzio C. et al. A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding. Neuropsychopharmacology 2006; 31: 1123-1134
  CrossrefPubMedGoogle Scholar
• 152 Sánchez-Lemus E, Honda M, Saavedra JM. et al. AT1 receptor blocker candesartan prevents the fast up-regulation of cerebrocortical benzodiazepine-1 receptors induced by acute inflammatory and restraint stress. Behav Brain Res 2012; 232: 84-92
  CrossrefPubMedGoogle Scholar
• 153 Khoury NM, Marvar PJ, Gillespie CF. et al. The renin-angiotensin pathway in posttraumatic stress disorder: angiotens inconverting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms. J Clin Psychiatry 2012; 73: 849-855
  CrossrefPubMedGoogle Scholar
• 154 Villapol S, Saavedra JM. Neuroprotective effects of angiotensin receptor blockers. Am J Hypertens 2015; 28: 289-299
  CrossrefPubMedGoogle Scholar
• 155 Benicky J, Sánchez-Lemus E, Honda M. et al. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 2011; 36: 857-870
  CrossrefPubMedGoogle Scholar
• 156 Benicky J, Sánchez-Lemus E, Pavel J. et al. Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol 2009; 29: 781-792
  CrossrefPubMedGoogle Scholar
• 157 Danielyan L, Lourhmati A, Verleysdonk S. et al. Angiotensin receptor type 1 blockade in astroglia decreases hypoxia-induced cell damage and TNF alpha release. Neurochem Res 2007; 32: 1489-1498
  CrossrefPubMedGoogle Scholar
• 158 Pang T, Benicky J, Wang J. et al. Telmisartan ameliorates lipopolysaccharide-induced innate immune response through peroxisome proliferator-activated receptor-γ activation in human monocytes. J Hypertens 2012; 30: 87-96
  CrossrefPubMedGoogle Scholar
• 159 Pang T, Wang J, Benicky J. et al. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation 2012; 9: 102
  PubMedGoogle Scholar
• 160 Sohn YI, Lee NJ, Chung A. et al. Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking. Biochem Biophys Res Commun 2013; 439: 464-470
  CrossrefPubMedGoogle Scholar
• 161 Noda A, Fushiki H, Murakami Y. et al. Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques. Nucl Med Biol 2012; 39: 1232-1235
  CrossrefPubMedGoogle Scholar
• 162 Shimizu K, Takashima T, Yamane T. et al. Whole-body distribution and radiation dosimetry of [11C]telmisartan as a biomarker for hepatic organic anion transporting polypeptide (OATP) 1B3. Nucl Med Biol 2012; 39: 847-853
  CrossrefPubMedGoogle Scholar
• 163 Diener HC. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs. J Hypertens Suppl 2009; 27: S31-S36
  CrossrefPubMedGoogle Scholar
• 164 Michalsen A, Wenzel RR, Mayer C. et al. Quality of life and psychosocial factors during treatment with antihypertensive drugs. A comparison of captopril and quinapril in geriatric patients. Herz 2001; 26: 468-476
  CrossrefPubMedGoogle Scholar
• 165 Muders F, Elsner D, Jandeleit K. et al. Chronic ACE inhibition by quinapril modulates central vasopressinergic system. Cardiovasc Res 1997; 34: 575-581
  CrossrefPubMedGoogle Scholar
• 166 Croog SH, Levine S, Testa MA. et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-1664
  CrossrefPubMedGoogle Scholar
• 167 Testa MA, Anderson RB, Nackley JF. et al. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. N Engl J Med 1993; 328: 907-913
  CrossrefPubMedGoogle Scholar
• 168 Dengerink HA, Mead JD, Bertilson HS. Individual differences in response to alcohol. Vasoconstriction and vasodilation. J Stud Alchol 1978; 39: 12-18
  PubMedGoogle Scholar
• 169 Cairns V, Keil U, Kleinbaum D. et al. Alcohol consumption as a risk factor for high blood pressure. Munich Blood Pressure Study. Hypertension 1984; 6: 124-131
  CrossrefPubMedGoogle Scholar
• 170 Grupp LA. The renin-angiotensin system: a multidimensional source of control over alcohol consumption. Alcohol Alcohol Suppl 1991; 1: 421-426
  PubMedGoogle Scholar
• 171 Lingham T, Perlanski E, Grupp LA. Angiotensin converting enzyme inhibitors reduce alcohol consumption: some possible mechanisms and important conditions for its therapeutic use. Alcohol Clin Exp Res 1990; 14: 92-99
  CrossrefPubMedGoogle Scholar
• 172 Wayner MJ, Polan-Curtain JL, Chiu SC. et al. Losartan reduces ethanol intoxication in the rat. Alcohol 1994; 11: 343-346
  CrossrefPubMedGoogle Scholar
• 173 Rose AK, Shaw SG, Prendergast MA. et al. The importance of glucocorticoids in alcohol dependence and neurotoxicity. Alcohol Clin Exp Res 2010; 34: 2011-2018
  CrossrefPubMedGoogle Scholar
• 174 Newton TF, De La Garza 2nd R, Grasing K. The angiotensin-converting enzyme inhibitor perindopril treatment alters cardiovascular and subjective effects of methamphetamine in humans. Psychiatry Res 2010; 179: 96-100
  CrossrefPubMedGoogle Scholar
• 175 Visniauskas B, Perry JC, Oliveira V. et al. Cocaine administration increases angiotensin I-converting enzyme (ACE) expression and activity in the rat striatum and frontal cortex. Neurosci Lett 2012; 506: 84-88
  CrossrefPubMedGoogle Scholar
• 176 Zolezzi JM, Santos MJ, Bastías-Candia S et al. PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation. Biol Rev Camb Philos Soc 2017 [Epub ahead of print]
  PubMed
• 177 Schupp M, Clemenz M, Gineste R. et al. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes 2005; 54: 3442-3452
  CrossrefPubMedGoogle Scholar
• 178 Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta 2007; 1771: 1031-1045
  CrossrefPubMedGoogle Scholar
• 179 Culman J, Zhao Y, Gohlke P. et al. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 2007; 28: 244-249
  CrossrefPubMedGoogle Scholar
• 180 Pilipović K, Župan Ž, Dolenec P. et al. A single dose of PPARγ agonist pioglitazone reduces cortical oxidative damage and microglial reaction following lateral fluid percussion brain injury in rats. Prog Neuro-Psychopharmacol Biol Psychiatry 2015; 59: 8-20
  CrossrefPubMedGoogle Scholar
• 181 Mandrekar-Colucci S, Karlo JC, Landreth GE. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci 2012; 32: 10117-10128
  CrossrefPubMedGoogle Scholar
• 182 Shindo T, Takasaki K, Uchida K. et al. Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer’s disease incorporating additional cerebrovascular disease factors. Biol Pharm Bull 2012; 35: 2141-2147
  CrossrefPubMedGoogle Scholar
• 183 Cheng H, Shang Y, Jiang L. et al. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer’s disease and mild-to-moderate Alzheimer's disease: a meta-analysis. Int J Neurosci 2016; 126: 299-307
  CrossrefPubMedGoogle Scholar
• 184 Barbiero JK, Santiago R, Tonin FS. et al. PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2014; 53: 35-44
  CrossrefPubMedGoogle Scholar
• 185 Dickey AS, Pineda VV, Tsunemi T. et al. PPARδ repression in Huntington’s disease and its essential role in CNS translate into a potent agonist therapy. Nature Medicine 2016; 22: 37-45
  CrossrefPubMedGoogle Scholar
• 186 Kariharan T, Nanayakkara G, Parameshwaran K. et al. Central activation of PPARgamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiol Aging 2015; 36: 1451-1461
  CrossrefPubMedGoogle Scholar
• 187 Min LJ, Mogi M, Shudou M. et al. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice. Hypertension 2012; 59: 1079-1088
  CrossrefPubMedGoogle Scholar
• 188 Ouk T, Potey C, Gautier S. et al. PPARs: a potential target for a disease-modifying strategy in stroke. Curr Drug Targets 2013; 14: 752-767
  CrossrefPubMedGoogle Scholar
• 189 Villapol S, Balarezo MG, Affram K. et al. Neurorestoration after traumatic brain injury through angiotensin II receptor blockage. Brain 2015; 138: 3299-3315
  CrossrefPubMedGoogle Scholar
• 190 Kemp DE, Ismail-Beigi F, Calabrese JR. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry 2009; 166: 619
  PubMedGoogle Scholar
• 191 Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S. et al. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry 2008; 69: 178-182
  CrossrefPubMedGoogle Scholar
• 192 Colle R, de Larminat D, Rotenberg S. et al. Pioglitazone could induce remission in major depression: a meta-analysis. Neuropsychiatr Dis Treat 2016; 13: 9-16
  CrossrefPubMedGoogle Scholar
• 193 Colle R, de Larminat D, Rotenberg S. et al. PPAR-γ Agonists for the Treatment of Major Depression: A Review. Pharmacopsychiatry 2017; 50: 49-55
  Article in Thieme ConnectPubMedGoogle Scholar
• 194 Martínez-Gras I, Pérez-Nievas BG, García-Bueno B. et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res 2011; 128: 15-22
  CrossrefPubMedGoogle Scholar
• 195 Yi Z, Fan X, Wang J. et al. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study. Psychiatry Res 2012; 200: 79-82
  CrossrefPubMedGoogle Scholar
• 196 Liu YR, Hu TM, Lan TH. et al. Association of the PPAR-γ gene with altered glucose levels and psychosis profile in schizophrenia patients exposed to antipsychotics. Psychiatry Investig 2014; 11: 179-185
  CrossrefPubMedGoogle Scholar
• 197 Brandl EJ, Tiwari AK, Zai CC. et al. No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. Psychiatry Res 2014; 219: 255-260
  CrossrefPubMedGoogle Scholar
• 198 Stopponi S, Somaini L, Cippitelli A. et al. Activation of nuclear PPARγ receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry 2011; 69: 642-649
  CrossrefPubMedGoogle Scholar
• 199 Mascia P, Pistis M, Justinova Z. et al. Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors. Biol Psychiatry 2011; 69: 633-641
  CrossrefPubMedGoogle Scholar
• 200 Jackson A, Bagdas D, Muldoon PP. et al. In vivo interactions between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α: Implication for nicotine dependence. Neuropharmacology 2017; 118: 38-45
  CrossrefPubMedGoogle Scholar
• 201 García-Bueno B, Madrigal JL, Lizasoain I. et al. Peroxisome proliferator-activated receptor gamma activation decreases neuroinflammation in brain after stress in rats. Biol Psychiatry 2005; 57: 885-894
  CrossrefPubMedGoogle Scholar
• 202 McIntyre RS, Soczynska JK, Lewis GF. et al. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin Pharmacother 2006; 7: 1305-1321
  CrossrefPubMedGoogle Scholar
• 203 Ryan KK, Grayson BE, Jones KR. et al. Physiological responses to acute psychological stress are reduced by the PPARγ agonist rosiglitazone. Endocrinology 2012; 153: 1279-1287
  CrossrefPubMedGoogle Scholar